Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study.
Direct acting antivirals
Hepatitis C
People who inject drugs
Qualitative research
Journal
International journal for equity in health
ISSN: 1475-9276
Titre abrégé: Int J Equity Health
Pays: England
ID NLM: 101147692
Informations de publication
Date de publication:
06 06 2023
06 06 2023
Historique:
received:
06
12
2022
accepted:
23
05
2023
medline:
8
6
2023
pubmed:
7
6
2023
entrez:
6
6
2023
Statut:
epublish
Résumé
Hepatitis C is curable with direct-acting antivirals (DAAs). However, treatment uptake remains low among marginalized populations such as people who inject drugs. We sought to understand challenges to treatment uptake with DAAs among people living with hepatitis C and compare treatment experiences between people who do and do not inject prescription and/or unregulated drugs. We conducted a qualitative study using focus groups with 23 adults aged 18 years and over who completed DAA treatment or were about to begin such treatment at the time of the study. Participants were recruited from hepatitis C treatment clinics across Toronto, Ontario. We drew upon stigma theory to interpret participants' accounts. Following analysis and interpretation, we generated five theoretically-informed themes characterizing the experiences of individuals accessing DAAs: "being 'worthy' of the cure", "spatially enacted stigma", "countering social and structural vulnerability: the importance of peers", "identity disruption and contagion: attaining a 'social cure'" and "challenging stigma with population-based screening". Overall, our findings suggest that structural stigma generated and reproduced through healthcare encounters limits access to DAAs among people who inject drugs. Peer-based programs and population-based screening were proposed by participants as mechanisms for countering stigma within health care settings and 'normalizing' hepatitis C among the general population. Despite the availability of curative therapies, access to such treatment for people who inject drugs is limited by stigma enacted in and structured within healthcare encounters. Developing novel, low-threshold delivery programs that remove power differentials and attend to the social and structural determinants of health and reinfection are needed to facilitate further scale up of DAAs and support the goal of eradicating hepatitis C as a public health threat.
Sections du résumé
BACKGROUND
Hepatitis C is curable with direct-acting antivirals (DAAs). However, treatment uptake remains low among marginalized populations such as people who inject drugs. We sought to understand challenges to treatment uptake with DAAs among people living with hepatitis C and compare treatment experiences between people who do and do not inject prescription and/or unregulated drugs.
METHODS
We conducted a qualitative study using focus groups with 23 adults aged 18 years and over who completed DAA treatment or were about to begin such treatment at the time of the study. Participants were recruited from hepatitis C treatment clinics across Toronto, Ontario. We drew upon stigma theory to interpret participants' accounts.
RESULTS
Following analysis and interpretation, we generated five theoretically-informed themes characterizing the experiences of individuals accessing DAAs: "being 'worthy' of the cure", "spatially enacted stigma", "countering social and structural vulnerability: the importance of peers", "identity disruption and contagion: attaining a 'social cure'" and "challenging stigma with population-based screening". Overall, our findings suggest that structural stigma generated and reproduced through healthcare encounters limits access to DAAs among people who inject drugs. Peer-based programs and population-based screening were proposed by participants as mechanisms for countering stigma within health care settings and 'normalizing' hepatitis C among the general population.
CONCLUSIONS
Despite the availability of curative therapies, access to such treatment for people who inject drugs is limited by stigma enacted in and structured within healthcare encounters. Developing novel, low-threshold delivery programs that remove power differentials and attend to the social and structural determinants of health and reinfection are needed to facilitate further scale up of DAAs and support the goal of eradicating hepatitis C as a public health threat.
Identifiants
pubmed: 37280588
doi: 10.1186/s12939-023-01924-4
pii: 10.1186/s12939-023-01924-4
pmc: PMC10243011
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
112Subventions
Organisme : CIHR
Pays : Canada
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Polaris Observatory HCV, Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–76.
Perlman DC, Jordan AE. The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: structural-level causes and interventions. Curr HIV/AIDS Rep. 2018;15:96–112.
pubmed: 29460225
pmcid: 5884743
Macalino GE, Hou JC, Kumar MS, Taylor LE, Sumantera IG, Rich JD. Hepatitis C infection and incarcerated populations. Int J Drug Policy. 2004;15:103–14.
Mateu-Gelabert P, Sabounchi NS, Guarino H, Ciervo C, Joseph K, Eckhardt BJ, et al. Hepatitis C virus risk among young people who inject drugs. Front Public Health. 2022;10:835836.
pubmed: 35968435
pmcid: 9372473
Tarasuk J, Zhang J, Lemyre A, Cholette F, Bryson M, Paquette D. National findings from the Tracks survey of people who inject drugs in Canada, phase 4, 2017–2019. Can Commun Dis Rep. 2020;46:138–48.
pubmed: 35283692
pmcid: 8868043
Craine N, Hickman M, Parry JV, Smith J, Walker AM, Russell D, et al. Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiol Infect. 2009;137:1255–65.
pubmed: 19224654
Harris M, Guy D, Picchio CA, White TM, Rhodes T, Lazarus JV. Conceptualising hepatitis C stigma: a thematic synthesis of qualitative research. Int J Drug Policy. 2021;96:103320.
pubmed: 34261587
Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019;114:150–66.
pubmed: 30035835
2017. Public Health Agency of Canada. Infographic: people living with hepatitis C (HCV), Canada, Ottawa. (ON): https://www.canada.ca/en/public-health/services/publications/diseases-conditions/infographic-people-living-with-hepatitis-c-2017.html . Accessed November 17, 2022.
Janjua NZ, Yu A, Kuo M, Alvarez M, Cook D, Wong J, et al. Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort. BMC Infect Dis. 2016;16:334.
pubmed: 27436414
pmcid: 4952323
Lourenço L, Kelly M, Tarasuk J, Stairs K, Bryson M, Popovic N, et al. The hepatitis C epidemic in Canada: an overview of recent trends in surveillance, injection drug use, harm reduction and treatment. Can Commun Dis Rep. 2021;47:561–70.
pubmed: 35692566
pmcid: 9126177
Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019;4:435–44.
pubmed: 30981685
pmcid: 6698583
Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41:790–800.
pubmed: 15791608
Lingala S, Ghany MG. Natural history of Hepatitis C. Gastroenterol Clin North Am. 2015;44:717–34.
pubmed: 26600216
pmcid: 5939344
Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting Agent Therapy for Hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166:637–48.
pubmed: 28319996
pmcid: 5486987
Suwanthawornkul T, Anothaisintawee T, Sobhonslidsuk A, Thakkinstian A, Teerawattananon Y. Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C genotype 1: a systematic review and network Meta-analysis. PLoS ONE. 2015;10:e0145953.
pubmed: 26720298
pmcid: 4701000
He N, Feng G, Hao S, Xu M, Liu J, Kong F, et al. The impact of direct-acting antivirals on quality of life in patients with hepatitis C virus infection: a meta-analysis. Ann Hepatol. 2022;27:100705.
pubmed: 35398571
Mazzaro C, Quartuccio L, Adinolfi LE, Roccatello D, Pozzato G, Nevola R, et al. A review on extrahepatic manifestations of Chronic Hepatitis C virus infection and the impact of direct-acting antiviral therapy. Viruses. 2021;13:2249.
pubmed: 34835054
pmcid: 8619859
Adinolfi LE, Petta S, Fracanzani AL, Coppola C, Narciso V, Nevola R, et al. Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: a prospective multicentre study. Atherosclerosis. 2020;296:40–7.
pubmed: 32005004
Butt AA, Yan P, Shuaib A, Abou-Samra AB, Shaikh OS, Freiberg MS. Direct-acting antiviral therapy for HCV infection is Associated with a reduced risk of Cardiovascular Disease events. Gastroenterology. 2019;156:987–996e8.
pubmed: 30445009
Hum J, Jou JH, Green PK, Berry K, Lundblad J, Hettinger BD, et al. Improvement in Glycemic Control of type 2 diabetes after successful treatment of Hepatitis C Virus. Diabetes Care. 2017;40:1173–80.
pubmed: 28659309
Harris RJ, Martin NK, Rand E, Mandal S, Mutimer D, Vickerman P, et al. New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. J Viral Hepat. 2016;23:631–43.
pubmed: 27025238
pmcid: 4982023
Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol. 2018;68:402–11.
pubmed: 29080808
pmcid: 5841161
Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57(Suppl 2):39–45.
WHO. Global health sector strategy on viral hepatitis 2016–2021. 2016.
Public Health Agency of Canada. Reducing the health impact of sexually transmitted and blood-borne infections in Canada by 2030: a pan-Canadian STBBI framework for action. Ottawa (ON). 2018. Available at: https://www.canada.ca/en/public-health/services/infectiousdiseases/sexual-health-sexually-transmitted-infections/reports-publications/sexually-transmitted-blood-borneinfections-action-framework.html . Accessed November 17, 2022.
Saeed S, Strumpf EC, Moodie EE, Young J, Nitulescu R, Cox J, et al. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. J Int AIDS Soc. 2017;20:e25013.
pubmed: 29116684
pmcid: 5810331
Bartlett SR, Yu A, Chapinal N, Rossi C, Butt Z, Wong S, et al. The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: impact of direct acting antivirals. Liver Int. 2019;39:2261–72.
pubmed: 31444846
Rhodes T, Harris M, Martin A. Negotiating access to medical treatment and the making of patient citizenship: the case of hepatitis C treatment. Sociol Health Illn. 2013;35:1023–44.
pubmed: 23701040
Clark JA, Gifford AL. Resolute efforts to cure hepatitis C: understanding patients’ reasons for completing antiviral treatment. Health (London). 2015;19:473–89.
pubmed: 25377666
Goodyear T, Brown H, Browne AJ, Hoong P, Ti L, Knight R. Stigma is where the harm comes from”: exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs. Int J Drug Policy. 2021;96:103238.
pubmed: 33902968
pmcid: 8881088
Goodyear T, Brown H, Browne AJ, Hoong P, Ti L, Knight R. I want to get better, but…identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments. Int J Equity Health. 2021;20:81.
pubmed: 33740984
pmcid: 7977167
Amoako A, Ortiz-Paredes D, Engler K, Lebouché B, Klein MB. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: a knowledge synthesis. Int J Drug Policy. 2021;96:103247.
pubmed: 33853727
Shakeri A, Hayes KN, Gomes T, Tadrous M. Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada. Can Liver J. 2021;4:426–9.
pubmed: 35989895
pmcid: 9235118
Public Health Agency of Canada. Report on, Hepatitis B, Surveillance in C. Canada: 2019;2022. Available at: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/report-hepatitis-b-c-canada-2019.html . Accessed November 17, 2022.
Saeed S, Strumpf E, Moodie EEM, Wong L, Cox J, Walmsley S, et al. Eliminating structural barriers: the impact of Unrestricted Access on Hepatitis C Treatment Uptake among People Living with Human Immunodeficiency Virus. Clin Infect Dis. 2020;71:363–71.
pubmed: 31504327
The Canadian Network on Hepatitis C Blueprint Writing Committee and Working Groups. Blueprint to inform hepatitis C elimination efforts in Canada. Montreal, QC: Available at: canhepc https://canhepc.ca/sites/default/files/media/documents/blueprint_hcv_2019_05.pdf . Accessed November 17, 2022.
Kuzel AJ. Sampling in qualitative inquiry. In: Crabtrree BF, Miller WL, editors. Doing qualitative research (second edition). Thousand Oaks, CA: Sage Publications; 1999. pp. 33–45.
Nyamathi A, Shuler P. Focus group interview: a research technique for informed nursing practice. J Adv Nurs. 1990;15:1281–8.
pubmed: 2269750
Hennink MM, Kaiser BN, Weber MB. What influences saturation? Estimating sample sizes in Focus Group Research. Qual Health Res. 2019;29:1483–96.
pubmed: 30628545
pmcid: 6635912
Charmaz K. Constructing grounded theory: a practical guide through qualitative analysis. Thousand Oaks: SAGE Publications Inc.; 2006.
Goffman E. Stigma; notes on the management of spoiled identity. Englewood Cliffs, N.J.: Prentice-Hall; 1963.
Link BG, Phelan JC. Conceptualizing stigma. Annu Rev Sociol. 2001;27:363–85.
Sandelowski M. Theory unmasked: the uses and guises of theory in qualitative research. Res Nurs Health. 1993;16:213–8.
pubmed: 8497673
Ayo N. Understanding health promotion in a neoliberal climate and the making of health conscious citizens. Crit Public Health. 2012;22:99–105.
Brown BJ, Baker S. Responsible citizens: individuals, health, and policy under neoliberalism. Anthem Press; 2012.
Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy. 2009;20:193–201.
pubmed: 19147339
Rhodes T, Treloar C. The social production of hepatitis C risk among injecting drug users: a qualitative synthesis. Addiction. 2008;103:1593–603.
pubmed: 18821870
Fraser S. It’s your life!‘: injecting drug users, individual responsibility and hepatitis C prevention. Health (London). 2004;8:199–221.
pubmed: 15068637
Zijlstra MK, Fidel Nague K, Louie P, Imas P, Sonnenberg A, Fimmel CJ. Successful Hepatitis C birth cohort screening and linkage to Care in a US Community Health System. J Public Health Manag Pract. 2022;28:E825–30.
pubmed: 36194824
pmcid: 9528933
Biondi MJ, Hirode G, Capraru C, Vanderhoff A, Karkada J, Wolfson-Stofko B, et al. Birth cohort hepatitis C antibody prevalence in real-world screening settings in Ontario. Can Liver J. 2022;5:362–71.
pubmed: 36133900
pmcid: 9473558
Ontario Breast Screening Program (OBSP). Available at: https://www.cancercareontario.ca/en/cancer-care-ontario/programs/screening-programs/ontario-breast-obsp . Accessed November 17, 2022.
ColonCancerCheck. Colorectal Screening Program. Available at: https://www.cancercareontario.ca/en/cancer-care-ontario/programs/screening-programs/colon-cancer-check-colorectal-screening . Accessed November 17, 2022.
Eckhardt B, Mateu-Gelabert P, Aponte-Melendez Y, Fong C, Kapadia S, Smith M, et al. Accessible Hepatitis C Care for People who inject drugs: a Randomized Clinical Trial. JAMA Intern Med. 2022;182:494–502.
pubmed: 35285851
pmcid: 8922207
Eckhardt BJ, Scherer M, Winkelstein E, Marks K, Edlin BR. Hepatitis C treatment outcomes for people who inject drugs treated in an Accessible Care Program located at a Syringe Service Program. Open Forum Infect Dis. 2018;5:ofy048.
pubmed: 29644246
pmcid: 5887278
Paterson B, Hirsch G, Andres K. Structural factors that promote stigmatization of drug users with hepatitis C in hospital emergency departments. Int J Drug Policy. 2013;24:471–8.
pubmed: 23453299
Asher AK, Portillo CJ, Cooper BA, Dawson-Rose C, Vlahov D, Page KA. Clinicians’ views of Hepatitis C Virus Treatment Candidacy with Direct-Acting antiviral regimens for people who inject drugs. Subst Use Misuse. 2016;51:1218–23.
pubmed: 27219274
pmcid: 6907073
Rogal SS, McCarthy R, Reid A, Rodriguez KL, Calgaro L, Patel K, et al. Primary care and Hepatology Provider-Perceived Barriers to and facilitators of Hepatitis C Treatment Candidacy and Adherence. Dig Dis Sci. 2017;62:1933–43.
pubmed: 28523579
Litwin AH, Drolet M, Nwankwo C, Torrens M, Kastelic A, Walcher S, et al. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: the C-SCOPE study. J Viral Hepat. 2019;26:1094–104.
pubmed: 31074167
pmcid: 6771477
Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3:153–61.
pubmed: 29310928
Graf C, Mücke MM, Dultz G, Peiffer KH, Kubesch A, Ingiliz P, et al. Efficacy of direct-acting antivirals for chronic Hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and Meta-analysis. Clin Infect Dis. 2020;70:2355–65.
pubmed: 31513710
Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, et al. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. Int J Drug Policy. 2018 Dec;62:94–103.
Tsui JI, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend. 2016;169:101–9.
pubmed: 27810652
pmcid: 6534140
Socías ME, Ti L, Dong H, Shoveller J, Kerr T, Montaner J, et al. High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs. HIV Med. 2017;18:647–54.
pubmed: 28294492
pmcid: 5819997
Boglione L, Mornese Pinna S, De Nicolò A, Cusato J, Cariti G, Di Perri G, et al. Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study. J Viral Hepat. 2017;24:850–7.
pubmed: 28345206
Donckier V, Lucidi V, Gustot T, Moreno C. Ethical considerations regarding early liver transplantation in patients with severe alcoholic hepatitis not responding to medical therapy. J Hepatol. 2014;60:866–71.
pubmed: 24291238
Rice JP, Lucey MR. Should length of sobriety be a major determinant in liver transplant selection? Curr Opin Organ Transplant. 2013;18:259–64.
pubmed: 23492643
Kirkpatrick JN, Smith JW. Dilemmas in Dual Disease: Complexity and Futility in Prosthetic Valve Endocarditis and Substance Use Disorder. Am J Bioeth. 2018;18:76–8.
pubmed: 29313791
Powell J, Ricco M, Naugle J, Magee C, Hassan H, Masson C, et al. Adherence to Hepatitis C therapy in a shelter-based education and treatment model among persons experiencing homelessness. Open Forum Infect Dis. 2021;8:ofab488.
pubmed: 34651053
pmcid: 8507447
Socías ME, Karamouzian M, Parent S, Barletta J, Bird K, Ti L. Integrated models of care for people who inject drugs and live with hepatitis C virus: a systematic review. Int J Drug Policy. 2019 Oct;72:146–59.
Tsui JI, Barry MP, Austin EJ, Sweek EW, Tung E, Hansen RN, et al. Treat my whole person, not just my condition’: qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Addict Sci Clin Pract. 2021;16:52.
pubmed: 34384494
pmcid: 8358259
Downes JM, Donovan A, McAdam-Marx C. Pharmacist-led drug therapy management for hepatitis C at a federally qualified health care center. J Am Pharm Assoc (2003). 2022;62:1596–1605.
Goodyear T, Ti L, Carrieri P, Small W, Knight R. Everybody living with a chronic disease is entitled to be cured”: Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs. Int J Drug Policy. 2020;81:102766.
pubmed: 32416525
Crawford S, Bath N. Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection. Clin Infect Dis. 2013;57(Suppl 2):75–9.
Rance J, Treloar C. We are people too”: consumer participation and the potential transformation of therapeutic relations within drug treatment. Int J Drug Policy. 2015;26:30–6.
pubmed: 24951024
Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health concern among people who inject drugs by 2030 - what will it take to get there? J Int AIDS Soc. 2017;20:22146.
pubmed: 28782335
pmcid: 5577699
Broad J, Mason K, Guyton M, Lettner B, Matelski J, Powis J. Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto, Canada. Int J Drug Policy. 2020;80:102755.
pubmed: 32416538
Canadian HIV/AIDS, Legal Network. “ Nothing About Us Without Us” Greater, Meaningful Involvement of People Who Use Illegal Drugs: A Public Health, Ethical, and Human Rights Imperative. Available at: http://www.hivlegalnetwork.ca/site/wp-content/uploads/2013/04/Greater+Involvement+-+Rpt+-+Drug+Policy+-+ENG.pdf . Accessed November 17, 2022.
Metzl JM, Hansen H. Structural competency: theorizing a new medical engagement with stigma and inequality. Soc Sci Med. 2014;103:126–33.
pubmed: 24507917
pmcid: 4269606
Bagchi AD. A structural competency curriculum for primary care providers to address the opioid use disorder, HIV, and Hepatitis C Syndemic. Front Public Health. 2020;8:210.
pubmed: 32582612
pmcid: 7289946
Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC Recommendations for Hepatitis C screening among adults - United States, 2020. MMWR Recomm Rep. 2020;69:1–17.
pubmed: 32614811
pmcid: 8631741
US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, et al. Screening for Hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;323:970–5.